OrganiGram (CVE:OGI) PT Set at C$9.00 by Raymond James

OrganiGram (CVE:OGI) received a C$9.00 price target from analysts at Raymond James in a research report issued on Wednesday, BayStreet.CA reports. The brokerage presently has an “outperform” rating on the stock.

A number of other equities research analysts also recently weighed in on the company. AltaCorp Capital dropped their target price on OrganiGram from C$13.15 to C$6.50 in a research report on Tuesday. Jefferies Financial Group upgraded OrganiGram from a “hold” rating to a “buy” rating and dropped their target price for the stock from C$10.50 to C$8.20 in a research report on Friday, October 11th. CIBC set a C$9.00 target price on OrganiGram and gave the stock an “outperform” rating in a research report on Tuesday, September 24th. Finally, Canaccord Genuity dropped their price objective on OrganiGram from C$8.50 to C$7.00 in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. OrganiGram has an average rating of “Buy” and a consensus target price of C$8.60.

The company has a market capitalization of $661.23 million and a P/E ratio of 28.02. OrganiGram has a 52-week low of C$4.11 and a 52-week high of C$11.30. The company has a current ratio of 9.06, a quick ratio of 4.14 and a debt-to-equity ratio of 14.71. The business’s fifty day moving average price is C$6.22 and its two-hundred day moving average price is C$7.97.

OrganiGram Company Profile

OrganiGram Holdings Inc, through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders.

See Also: How to calculate the annual rate of depreciation

Analyst Recommendations for OrganiGram (CVE:OGI)

Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with's FREE daily email newsletter.